Show simple item record

dc.contributor.authorBukhari, Sarah I.
dc.contributor.authorImam, Syed Sarim
dc.contributor.authorAhmad, Mohammad Zaki
dc.contributor.authorVuddanda, Parameswara Rao
dc.contributor.authorAlshehri, Sultan
dc.contributor.authorMahdi, Wael A.
dc.contributor.authorAhmad, Javed
dc.date.accessioned2021-09-01T13:00:02Z
dc.date.available2021-09-01T13:00:02Z
dc.date.issued2021-06-07
dc.identifier.citationBukhari , S I , Imam , S S , Ahmad , M Z , Vuddanda , P R , Alshehri , S , Mahdi , W A & Ahmad , J 2021 , ' Recent Progress in Lipid Nanoparticles for Cancer Theranostics: Opportunity and Challenges ' , Pharmaceutics , vol. 13 , no. 6 , pp. e840 . https://doi.org/10.3390/pharmaceutics13060840
dc.identifier.issn1999-4923
dc.identifier.otherPURE: 25862405
dc.identifier.otherPURE UUID: 0f90183a-0733-4c2e-a06f-84789e8ee6ec
dc.identifier.otherJisc: cd81f0cde5b04e87b585a4a944bb0015
dc.identifier.otherScopus: 85107678585
dc.identifier.urihttp://hdl.handle.net/2299/25027
dc.description.abstractCancer is one of the major leading causes of mortality in the world. The implication of nanotherapeutics in cancer has garnered splendid attention owing to their capability to efficiently address various difficulties associated with conventional drug delivery systems such as non-specific biodistribution, poor efficacy, and the possibility of occurrence of multi-drug resistance. Amongst a plethora of nanocarriers for drugs, this review emphasized lipidic nanocarrier systems for delivering anticancer therapeutics because of their biocompatibility, safety, high drug loading and capability to simultaneously carrying imaging agent and ligands as well. Furthermore, to date, the lack of interaction between diagnosis and treatment has hampered the efforts of the nanotherapeutic approach alone to deal with cancer effectively. Therefore, a novel paradigm with concomitant imaging (with contrasting agents), targeting (with biomarkers), and anticancer agent being delivered in one lipidic nanocarrier system (as cancer theranostics) seems to be very promising in overcoming various hurdles in effective cancer treatment. The major obstacles that are supposed to be addressed by employing lipidic theranostic nanomedicine include nanomedicine reach to tumor cells, drug internalization in cancer cells for therapeutic intervention, off-site drug distribution, and uptake via the host immune system. A comprehensive account of recent research updates in the field of lipidic nanocarrier loaded with therapeutic and diagnostic agents is covered in the present article. Nevertheless, there are notable hurdles in the clinical translation of the lipidic theranostic nanomedicines, which are also highlighted in the present review along with plausible countermeasures.en
dc.language.isoeng
dc.relation.ispartofPharmaceutics
dc.rightsOpen
dc.subjectcancer
dc.subjectmulti-drug resistance
dc.subjectenhanced permeation and retention effect
dc.subjectnanotherapeutics
dc.subjectcancer theranostic
dc.subjectclinical translation
dc.titleRecent Progress in Lipid Nanoparticles for Cancer Theranostics: Opportunity and Challengesen
dc.contributor.institutionCentre for Research into Topical Drug Delivery and Toxicology
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionToxicology
dc.description.statusPeer reviewed
dc.relation.schoolSchool of Life and Medical Sciences
dc.description.versiontypeFinal Published version
dcterms.dateAccepted2021-06-07
rioxxterms.versionVoR
rioxxterms.versionofrecordhttps://doi.org/10.3390/pharmaceutics13060840
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/
rioxxterms.typeOther
herts.preservation.rarelyaccessedtrue
herts.rights.accesstypeOpen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record